Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892592 | 0.90 | EGFR (0.41) | EGFRERBB2KDRPDGFRBIMPDH2 | |
| SCHEMBL4896850 | 0.84 | EGFR (0.41) | EGFRERBB2KDRPDGFRB | |
| SCHEMBL4720811 | 0.82 | EGFR (0.40) | EGFRERBB2EIF2AK2 | |
| SCHEMBL4717449 | 0.82 | KMT2A (0.53) | PDGFRBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4912909 | 0.81 | EGFR (0.39) | EGFRERBB2MEN1KMT2A | |
| SCHEMBL4720750 | 0.80 | EGFR (0.38) | EGFRERBB2 | |
| SCHEMBL4891766 | 0.80 | CYP1A2 (0.46) | EGFRERBB2MEN1KMT2A | |
| SCHEMBL4718840 | 0.78 | MAPK14 (0.54) | ERBB2 | |
| SCHEMBL5319652 | 0.76 | EGFR (0.44) | EGFRERBB2KDRPDGFRB | |
| SCHEMBL4714761 | 0.74 | FGFR1 (0.38) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | EGFR 369/4885ERBB2 38/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.